ABVC BioPharma announced that Vitargus Phase II Site Initiation Visit at Srinagarind Hospital, Khon Kaen University was successfully conducted on March 9-10. The SIV was an organized meeting to discuss Phase II study protocol with the principal investigator and begin training clinical personnel.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABVC:
- ABVC BioPharma’s Maitake Mushroom Dietary Supplement approved in Taiwan
- ABVC BioPharma provides 2023 pipeline update
- ABVC BioPharma Provides 2023 Pipeline Update
- ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
- ABVC receives Australian TGA approval to initiate Phase II study of vitargus